Physician profile
Caron Harner
NPI 1801106984
$11,309.80
in general payments reported to CMS, 2019-2025
34 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 86% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,438 · 2020: $872 · 2021: $466 · 2022: $329 · 2023: $2,590 · 2024: $2,317 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,939 · Food and Beverage: $3,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,938.63 |
| Food and Beverage | $3,266.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $7,058.37 | 2019-2025 | Prostep, Ortholoc 3di, Prophecy |
| Biotissue Holdings INC. | $1,774.02 | 2024-2025 | |
| Smith+Nephew, INC. | $523.76 | 2020-2025 | Bone Anchors With Arthroscopic Delivery System, Stravix, Grafix Pl |
| Horizon Therapeutics Plc | $384.08 | 2019-2021 | |
| Paragon 28, INC. | $312.80 | 2019-2024 | Gorilla |
| Treace Medical Concepts, INC. | $214.90 | 2022-2024 | |
| Imperative Care, INC | $147.19 | 2023 | Prodigy Catheter |
| Paratek Pharmaceuticals, INC. | $129.09 | 2020-2025 | Nuzyra |
| Zimmer Biomet Holdings, INC. | $117.30 | 2020 | |
| Nevro Corp. | $93.93 | 2022-2023 | Senza |
| Legacy Ortho LLC | $66.65 | 2025 | |
| Wright Medical Technology, INC. | $51.95 | 2020 | |
| Integra Lifesciences Corporation | $51.34 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Aroa Biosurgery Incorporated | $35.39 | 2025 | |
| Dexcom, INC. | $30.76 | 2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $27.56 | 2023 | |
| Globus Medical, INC. | $24.42 | 2025 | Senza |
| Averitas Pharma INC. | $21.51 | 2023 | Qutenza |
| Solventum Corporation | $21.21 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Ibsa Pharma INC. | $20.67 | 2024 | Licart, Tirosint |
| Dynavax Technologies Corporation | $19.89 | 2025 | Heplisav-B |
| Acera Surgical, INC. | $17.66 | 2024 | Restrata Wound Matrix |
| Ani Pharmaceuticals, INC. | $17.20 | 2023 | Purified Cortrophin Gel |
| Heron Therapeutics, INC. | $17.09 | 2021 | |
| Medtronic, INC. | $15.87 | 2021 | |
| Molnlycke Health Care US, LLC | $14.75 | 2025 | Mepilex, Exufiber Ag+, Mepilex Border Flex |
| Bioventus LLC | $13.43 | 2024 | Exogen Ultrasound Bone Healing System |
| Merck Sharp & Dohme LLC | $13.33 | 2019 | |
| Arteriocyte Medical Systems, INC. | $13.20 | 2019 | |
| Organogenesis INC. | $12.72 | 2023 | Puraply |
| Grt US Holding, INC. | $12.64 | 2021 | |
| Reprise Biomedical, INC. | $12.34 | 2025 | Miro3d |
| Bsn Medical INC | $11.78 | 2020 | |
| Zyla Life Sciences, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caron Harner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.